Top Page
Resonance Health Ltd
(Sydney:RHT)
Resonance Health Ltd (RHT) vs. iShares MSCI Australia ETF (EWA)
Resonance Health Ltd Business Overview & Revenue Model
Resonance Health Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.07M | 11.07M | 8.59M | 4.40M | 3.83M | 3.78M |
| Gross Profit | 11.07M | 11.07M | 8.59M | 4.40M | 3.83M | 3.78M |
| EBITDA | -1.41M | -1.41M | -382.00K | -1.19M | -1.34M | 707.69K |
| Net Income | -1.73M | -1.73M | 169.30K | -780.00K | -1.14M | 585.86K |
Balance Sheet | ||||||
| Total Assets | 17.89M | 17.89M | 20.28M | 10.98M | 11.69M | 12.44M |
| Cash, Cash Equivalents and Short-Term Investments | 2.98M | 2.98M | 6.85M | 6.36M | 6.78M | 8.86M |
| Total Debt | 3.80M | 3.80M | 3.70M | 272.94K | 268.22K | 60.10K |
| Total Liabilities | 8.50M | 8.50M | 9.35M | 1.05M | 995.58K | 611.74K |
| Stockholders Equity | 9.39M | 9.39M | 10.93M | 9.94M | 10.69M | 11.83M |
Cash Flow | ||||||
| Free Cash Flow | 805.39K | 805.39K | 1.01M | -624.93K | -1.42M | 772.72K |
| Operating Cash Flow | 1.25M | 1.25M | 1.39M | -157.03K | -712.67K | 1.17M |
| Investing Cash Flow | -4.52M | -4.52M | -3.94M | -467.90K | -704.00K | -395.79K |
| Financing Cash Flow | -649.26K | -649.26K | 3.01M | -81.97K | -107.11K | 1.20M |
Resonance Health Ltd Technical Analysis
Resonance Health Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | AU$87.68M | ― | -8647.54% | ― | 25.98% | 21.43% | |
| ― | AU$12.40M | -2.67 | -27.84% | ― | 6.77% | -8.45% | |
| ― | AU$23.07M | 140.00 | -17.05% | ― | 28.91% | -1050.00% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | AU$42.73M | ― | -81.30% | ― | -36.68% | 79.41% | |
| ― | AU$10.24M | ― | ― | ― | -40.05% | -49.57% | |
| ― | AU$89.08M | -12.56 | ― | ― | ― | ― |
Resonance Health Ltd Corporate Events
Resonance Health Ltd has announced the details of its 2025 Annual General Meeting (AGM), scheduled for November 13, 2025, in Perth, Western Australia. Shareholders can participate in the AGM in person or by proxy, with specific instructions provided for voting. The company will not send physical copies of the meeting notice to shareholders who have not opted for electronic communication, emphasizing the importance of accessing the notice online. This announcement underscores the company’s commitment to efficient shareholder communication and engagement.
Resonance Health Ltd has announced an investor strategy day, inviting stakeholders to join a live webcast hosted by key company executives. The event aims to provide insights into the company’s strategic direction and will be available for later viewing. This initiative underscores Resonance Health’s commitment to transparency and engagement with its stakeholders, potentially strengthening its market position and fostering investor confidence.
Resonance Health Ltd has announced the appointment of Andrew Harrison as a director, effective October 1, 2025. Harrison holds significant interests in the company, including 8 million ordinary fully paid shares and additional loan shares through a family trust. This appointment and Harrison’s substantial shareholding may influence the company’s strategic direction and stakeholder interests.
Resonance Health Ltd announced significant leadership changes with Dr. Martin Blake retiring as Chair and Non-Executive Director, to be succeeded by Mr. Aaron Brinkworth following the AGM on November 13, 2025. Mr. Andrew Harrison, the current CEO, will also take on the role of Managing Director, reflecting the company’s strategic focus on governance and growth. These changes are expected to strengthen Resonance Health’s position in the healthcare technology industry, as the company continues to expand its portfolio and global reach.
Resonance Health Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the extent to which the company has adhered to the ASX Corporate Governance Council’s recommendations, providing transparency in its governance practices and ensuring accountability to its stakeholders.
Resonance Health Ltd has released updated shareholder information in compliance with ASX Listing Rule 4.10. This update includes details on corporate governance, securities distribution, and the top twenty security holders. The announcement replaces previous shareholder information from the company’s annual report and reflects the company’s commitment to transparency and regulatory compliance.
Resonance Health Ltd announced its full-year financial results for FY25 and provided guidance for FY26. The company is hosting a live investor briefing to discuss these results, which reflects its ongoing commitment to innovation and quality in healthcare technology. This announcement is significant for stakeholders as it highlights Resonance Health’s strategic direction and potential growth in the healthcare technology sector.
Resonance Health Limited reported a significant increase in revenue by 29% to $11.07 million for the year ending June 30, 2025, compared to the previous year. However, the company faced a net loss of $1.73 million, a sharp decline from the previous year’s profit of $169,303. This financial downturn, despite increased revenues, indicates challenges in managing operational costs or other financial pressures, impacting the company’s profitability and potentially affecting stakeholder confidence.
Resonance Health Ltd has announced its intention to release its full-year results for FY25 and guidance for FY26 on the ASX by 29 August 2025. The company will host a webinar for investors and analysts to discuss these results, encouraging stakeholder engagement through interactive participation. This announcement reflects Resonance Health’s commitment to transparency and stakeholder communication, potentially impacting its market positioning and investor relations.
Resonance Health Ltd has announced the application for the quotation of 11,145,177 new ordinary fully paid securities on the ASX, issued under an employee incentive scheme. This move is expected to enhance the company’s operational capabilities and potentially strengthen its market position by incentivizing employees, aligning their interests with those of shareholders.
Resonance Health Ltd reported a positive net cash inflow from operations of $1.3 million for the full year, with significant progress in its clinical trial management and software-as-a-medical-device divisions. The company achieved profitability at its second TrialsWest site and secured new service contracts worth $4.5 million, reflecting growing demand for its imaging analysis services. The opening of a third clinical trial site and the development of a new ‘bridge’ technology to improve customer integration are expected to support future growth.